Your files are attached and ready to send with this message.

http://www.neurochem.com/AffDrCamp.pdf

About Neurochem

Neurochem is focused on the development and commercialization of
innovative therapeutics for neurological disorders. The Company's
pipeline of proprietary, disease-modifying, oral products addresses
critical unmet medical needs. FibrillexT, designated an orphan drug and
a Fast Track Product candidate, is in a Phase II/III clinical trial for
AA amyloidosis. AlzhemedT and CerebrilT have completed a Phase II
clinical trial for Alzheimer's Disease and for the prevention of
Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, respectively.
For additional information on Neurochem, please visit our website at :
(www.neurochem.com).